Eli Lilly & Company is projected to have the best earnings growth for the next 5 years, according to Cantor Fitzgerald. The exclusion of their oral GLP-1 treatment from the first group of medications to receive Commissioner’s National Priority Vouchers caused stock pressure in after-hours trading.

The news coincided with conflicting GLP-1 pricing discussions, possibly related to semaglutide pricing under the Inflation Reduction Act. Eli Lilly & Company, a major global pharmaceutical company, was founded in 1876 and has become one of the largest pharmaceutical companies in the world.

While Eli Lilly offers investment potential, some AI stocks are seen as having greater upside and lower downside risk. For those interested in undervalued AI stocks benefiting from Trump-era tariffs, a free report is available on the best short-term AI stock.

For more investing insights, check out the 10 Best Magic Formula Stocks for 2025 and the 10 Best Retirement Stocks to Buy According to Hedge Funds. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Cantor Fitzgerald Reaffirms Price Target on Eli Lilly (LLY) Despite GLP-1 Setback